Gapping down
In reaction to earnings/guidance:
- VRT -40.1%, RXT -23.2%, CSGP -23.1%, MNDY -16.3%, WK -12.4%, VIPS -10.1%, BCRX -8.8%, RSKD -7.4%, TJX -7.4%, SPNS -6.2%, PUMP -5.5%, MOS -4.9% (announces dividend target increase; also new $1 bln share repurchase program), SBGI -3.7%, BHC -3.4%, APG -3.2%, TUP -3%, JBT -2.5%, NI -2.1%, PRG -2%, API -1.7% (also approves $200 mln ADS repurchase program), TDOC -1.3%, NHI -1.3%, FYBR -1.3%, NDSN -1%, BTG -1%, PEN -0.9%, RIO -0.9%, BCO -0.8%, ROCK -0.8%
Other news:
- KOD -68.7% (announces top-line results from its initial Phase 2b/3 Study of KSI-301 in patients with neovascular (wet) age-related macular degeneration; did not meet the primary endpoint)
- OCGN -19.6% (prices offering of 15973420 mln shares of its common stock for gross proceeds of ~$53.5 mln)
- MRNS -10.6% (to delay RAISE Phase 3 trial in status epilepticus and associated IV ganaxolone clinical trials)
- CNHI -2.1% (announces updated 2024 strategic plan and presents 3-yr targets)
- NCNA -1% (completes enrollment for Phase III NuTide:121 study)
Analyst comments:
- MAX -2.8% (downgraded to Neutral from Buy at Citigroup)
- DV -2.5% (downgraded to Neutral from Overweight at JP Morgan)
- NOV -2.5% (downgraded to Sell from Neutral at Goldman)